The original Notice was dispatched to shareholders on August 27, 2026, seeking approval for:
- Alteration of the Main Object Clause of the Memorandum of Association (MOA)
- Change of company name from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited"
Nature of Corrigendum
The corrigendum replaces the original Independent Auditor's Certificate (Annexure-A) with a Revised Auditor's Certificate dated September 16, 2026, issued by the Statutory Auditors, M/s Shah Sanghvi & Associates, Chartered Accountants. This revision was made following observations from BSE Limited to provide detailed numerical parameters strictly aligning with the layout mandated under Regulation 45 of the SEBI (LODR) Regulations, 2015.
Key Financial Disclosures from Revised Certificate
The Revised Auditor's Certificate provides the following numerical data for the period from July 1, 2025 to June 30, 2026 (last four quarters):
Revenue Analysis:
- Income from prior business activity (Pharmaceuticals): ₹74.8373 crore (100% of total income)
- Income from new business activity (Medical Technology): ₹0 (0% of total income)
- Total income: ₹74.8373 crore
Asset Investment Analysis:
- Investment in new business activity (Medical Technology): ₹50.5831 crore (51.04% of total assets)
- Investment in old business activity (Pharmaceuticals): ₹48.5218 crore (48.96% of total assets)
- Total investment: ₹99.1049 crore
Detailed Breakdown of New Business Investment (Medical Technology):
- Fixed Asset: ₹17.7071 crore
- Advances: ₹6.2040 crore
- WIP/Inventories: ₹8.0108 crore
- Investment: ₹10.4787 crore
- Trade Receivable: ₹7.6900 crore
- Cash & Cash Equivalent: ₹0.4925 crore
- Total: ₹50.5831 crore
Detailed Breakdown of Old Business Investment (Pharmaceuticals):
- Fixed Asset: ₹15.2919 crore
- WIP/Inventories: ₹15.4047 crore
- Trade Receivable: ₹17.8252 crore
- Total: ₹48.5218 crore
Voting Process Update
The remote e-voting period commenced on August 28, 2026 (09:00 AM IST) and concludes on September 26, 2026 (05:00 PM IST). Shareholders who have already voted are permitted to log into the NSDL e-voting platform and cast their vote again. If a shareholder votes again, their subsequent/latest electronic vote will supersede and cancel out the previously cast vote. Shareholders who do not wish to change their vote will have their originally recorded vote considered as final.
Additional Information
The corrigendum is being dispatched electronically to all eligible members and is available on the company's website. All other contents, details, and timelines of the original Notice remain unchanged. The company has not changed its name in the last one year, fulfilling the time requirement under Regulation 45(1)(a).